Table 1 Characteristics of primary BPDCN patients’ samples.

From: Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Identifier (sample source)

Cytogenetic abnormality

Mutations

Clinical Status

Blast %

BPDCN-1 (PB)

ND

ASXL1, JAK2, TET2, NRAS

Relapse

46

BPDCN-2 (BM)

Add(17)(p11.2), TP53 deletion by FISH

ND

Relapse

10

BPDCN-3 (BM)

46,XY,t(1;6)(p21;p36.3), del(5)(q13q33), der(7)t(1;7)(q12;p22), del(11)(q13q23),del(12)(p11.2p13), add(15)(q15)

None identified

Relapse/ refractory

60

BPDCN-4 (BM)

45, XY, t(1;9)(p34;q32), del(6)(q16q27), der(6)t(3;6)(q26;p25), -21, add(21)(p13)[9]/46, XY[11]

TET2

Relapse

64

BPDCN-5 (PB)

46,XY, +1, add(1)(p13),der(1)dup(1)(q21q32)add(1)(q42),add(2)(p24),-4

MPL, TET2

Relapse

22

BPDCN-6(BM)

Add(12)(p11.2), -13, -21, +2~3mar[cp6]/46, XY

TET2, IDH2

Newly diagnosed

72

BPDCN-7 (PB)

diploid

ND

Newly diagnosed

32

BPDCN-8 (BM)

46,XY,del(9)(q21)[8]/46,XY[3]

TP53 x2, ZRSR2, IDH2

Newly diagnosed

90

  1. All samples were obtained from patients of male gender.
  2. PB peripheral blood, ND not determined, BM bone marrow, FISH fluorescence in situ hybridization.
Back to article page